Asset Details
Do you wish to reserve the book?
A microfluidics platform for combinatorial drug screening on cancer biopsies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A microfluidics platform for combinatorial drug screening on cancer biopsies
Do you wish to request the book?
A microfluidics platform for combinatorial drug screening on cancer biopsies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A microfluidics platform for combinatorial drug screening on cancer biopsies
2018
Overview
Screening drugs on patient biopsies from solid tumours has immense potential, but is challenging due to the small amount of available material. To address this, we present here a plug-based microfluidics platform for functional screening of drug combinations. Integrated Braille valves allow changing the plug composition on demand and enable collecting >1200 data points (56 different conditions with at least 20 replicates each) per biopsy. After deriving and validating efficient and specific drug combinations for two genetically different pancreatic cancer cell lines and xenograft mouse models, we additionally screen live cells from human solid tumours with no need for ex vivo culturing steps, and obtain highly specific sensitivity profiles. The entire workflow can be completed within 48 h at assay costs of less than US$ 150 per patient. We believe this can pave the way for rapid determination of optimal personalized cancer therapies.
Cancer patients exhibit specific sensitivities toward drug combinations that cannot be easily predicted. Here the authors setup a microfluidic platform that allows testing of multiple drug combinations correctly predicting sensitivity in vivo and they use it on patients biopsies to define effective drugs.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 49/62
/ Animals
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biopsy
/ Braille
/ Cancer
/ Drug Screening Assays, Antitumor - economics
/ Drug Screening Assays, Antitumor - instrumentation
/ Drug Screening Assays, Antitumor - methods
/ Female
/ High-Throughput Screening Assays - economics
/ High-Throughput Screening Assays - instrumentation
/ High-Throughput Screening Assays - methods
/ Humanities and Social Sciences
/ Humans
/ Mice
/ Microfluidics - instrumentation
/ Precision Medicine - methods
/ Science
/ Tumors
/ Workflow
